Medical Diagnostic Laboratories, L.L.C., (MDL), member of Genesis Biotechnology Group
® (GBG) and CLIA-certified, CAP-accredited laboratory specializing in high-complexity, state-of-the-art, automated DNA-based molecular analyses, launched a new line of testing for the field of Urology. This testing, available through
Uroveda Institute of Urogenital Diseases, an MDL Center of Excellence, blends DNA-based molecular testing with traditional pathology and cytology tests to aid in diagnosing or screening for urologic conditions.
Genesis Biotechnology Group
According to the National Institutes of Health (NIH), medical care costs for urologic diseases in the United States neared $11 billion in 2020. Urologic malignancies such as prostate, bladder, and renal cancers present challenges in diagnoses, treatment decisions, monitoring, and recurrence testing. Prostate, bladder, and renal cancers rank second, seventh, and ninth, respectively, in the top 10 cancers in the US based on new